Related Experiment Video
Updated: Jun 23, 2025
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Discovery of a potent CDKs/FLT3 PROTAC with enhanced differentiation and proliferation inhibition for AML
Mingfei Wu1, Wei Wang2, Xinfei Mao2
1Hangzhou Institute of Innovative Medicine, Institute of Drug Discovery and Design, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, PR China.
Abstract:
AML is an aggressive malignancy of immature myeloid progenitor cells. Discovering effective treatments for AML through cell differentiation and anti-proliferation remains a significant challenge. Building on previous studies on CDK2 PROTACs with differentiation-inducing properties, this research aims to enhance CDKs degradation through structural optimization to facilitate the differentiation and inhibit the proliferation of AML cells. Compound C3, featuring a 4-methylpiperidine ring linker, effectively degraded CDK2 with a DC50 value of 18.73 ± 10.78 nM, and stimulated 72.77 ± 3.51 % cell differentiation at 6.25 nM in HL-60 cells. Moreover, C3 exhibited potent anti-proliferative activity against various AML cell types. Degradation selectivity analysis indicated that C3 could be endowed with efficient degradation of CDK2/4/6/9 and FLT3, especially FLT3-ITD in MV4-11 cells. These findings propose that C3 combined targeting CDK2/4/6/9 and FLT3 with enhanced differentiation and proliferation inhibition, which holds promise as a potential treatment for AML.
Insights
A novel compound, C3, effectively targets and degrades key proteins in acute myeloid leukemia (AML) cells, promoting cell differentiation and inhibiting proliferation. This research offers a promising new therapeutic strategy for AML treatment.
Area of Science:
- Oncology
- Molecular Biology
- Medicinal Chemistry
Background:
- Acute myeloid leukemia (AML) is a challenging hematologic malignancy characterized by immature myeloid progenitor cells.
- Developing effective AML treatments that induce cell differentiation and inhibit proliferation remains a critical unmet need.
- Previous research has explored Cyclin-Dependent Kinase (CDK) PROTACs for their differentiation-inducing potential in AML.
Purpose of the Study:
- To structurally optimize PROTACs to enhance the degradation of CDKs, thereby promoting AML cell differentiation and inhibiting proliferation.
- To investigate the efficacy of a novel compound, C3, in degrading target proteins and its impact on AML cell behavior.
- To assess the degradation selectivity profile of C3 against various CDKs and FMS-like tyrosine kinase 3 (FLT3).
Main Methods:
- Synthesis and structural optimization of PROTAC compounds targeting CDKs.
- Evaluation of compound C3's CDK2 degradation efficiency using DC50 values in AML cell lines.
- Assessment of C3's ability to induce cell differentiation in HL-60 cells.
- Analysis of C3's anti-proliferative activity across different AML cell types.
- Degradation selectivity profiling of C3 against CDK family members and FLT3, including FLT3-ITD.
Main Results:
- Compound C3 demonstrated potent degradation of CDK2 with a low DC50 value (18.73 ± 10.78 nM).
- C3 significantly stimulated cell differentiation in HL-60 cells at a concentration of 6.25 nM (72.77 ± 3.51%).
- C3 exhibited strong anti-proliferative effects against various AML cell lines.
- Degradation analysis revealed C3's ability to degrade CDK2/4/6/9 and FLT3, particularly FLT3-ITD in MV4-11 cells.
Conclusions:
- Compound C3 effectively degrades CDK2 and induces differentiation and proliferation inhibition in AML cells.
- C3's ability to simultaneously target multiple CDKs and FLT3 presents a promising multi-targeted therapeutic strategy for AML.
- The findings support C3 as a potential novel therapeutic agent for treating acute myeloid leukemia.
Related Concept Videos
02:34Inhibition of Cdk Activity
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:15Differentiation of Common Myeloid Progenitor Cells